Macau's First Yescarta® CAR-T Cell Therapy Center Launched at Kiang Wu Hospital

Mr. Xie Xuebin, Vice President of Jinghu Hospital, stated:

"Very pleased that the CAR-T cell therapy technology has been applied at Jinghu Hospital. In the future, patients in Macao will also have access to world-leading CAR-T treatment, with significantly shortened treatment cycles and notably improved chances of cure. Jinghu Hospital has long been committed to the clinical application of innovative technologies, introducing multiple new treatment methods in recent years to provide patients with better outcomes and fewer side effects. CAR-T technology has opened up a new chapter in cellular therapy for cancer patients, bringing them renewed hope. Jinghu Hospital will maintain a proactive stance, continuously exploring new therapies, aligning with the new industrial policies of the Macao SAR government, striving in the Greater Health sector under the '1+4 Appropriate Economic Diversification Development Strategy' to offer high-quality medical services to patients."

Chen Xingrong, CEO of Fosun Kite Biotechnology Co., Ltd., said:

"This time, Yikaida^®The successful approval and launch of our product at Kiang Wu Hospital in Macao, China, has filled us with great excitement. Fosun Kite will bring high-quality CAR-T medications to the residents of Macao, filling the gap in the field of cellular therapy in the region through excellent real-world efficacy and stable pharmaceutical quality control. This will benefit lymphoma patients in Macao and allow more people in the Greater Bay Area to access premium medical resources.

The CAR-T cell therapy center at Kiang Wu Hospital in Macao uses the CAR-T drug Yikaida produced by Fosun Kite Biotechnology Co., Ltd.^®, characterized by individualized customization and one-time therapy, requires a separate production line for each patient, completed through more than 600 strict processes and over 20 professional preparation engineers. The product then undergoes rigorous quality control and inspection steps, a well-established logistics distribution system, and a professional patient service team to ensure timely reinfusion into the patient's body. Since its approval for marketing by the National Medical Products Administration in June 2021,Yikaida^®Successfully Treated Over 700 Lymphoma Patients. In June 2023, Yikaida^®New Second-Line Indication Approved for Market Launch: Treatment for Adult Patients with Large B-Cell Lymphoma Who Are Ineffective to First-Line Immunochemotherapy or Relapsed within 12 Months after First-Line Immunochemotherapy. This advancement in the treatment of adult large B-cell lymphoma brings hope to more patients who are ineffective to first-line immunochemotherapy or relapsed. The cooperation with Kiang Wu Hospital in Macao will enable Yikaida.^®Benefiting more patients in the Guangdong-Hong Kong-Macao Greater Bay Area.

The CAR-T cell therapy system involves multiple processes and links at the hospital end, manufacturing end, and logistics end. Each link has very high requirements for medical institutions and healthcare professionals. Therefore,Macau Kiang Wu Hospital specially appoints Professor Tongyu Lin, Chairman of the Tumor Society of the Chinese Medical Association and President of Sichuan Cancer HospitalAuthoritative experts in the field of oncology in China serve as advisors to the CAR-T project team, providing full guidance for the standardized construction and safe operation of the CAR-T cell therapy center. At the same time, to ensure the safe implementation of CAR-T cell therapy at Kiang Wu Hospital in Macao, Fosun Kite has collaborated with Hong Kong Jacobson and its subsidiary Macao Medical Supplies Co., Ltd. to support the hospital in carrying out comprehensive preparations. Starting from the second half of 2022, a thorough, systematic, and rigorous institutional certification process was completed over the course of more than a year. This included multiple modules of end-to-end work such as multi-stage personnel training, assessments, on-site audits, and live drills, offering full protection for patients.

Moreover, relevant regulatory authorities and partner enterprises in Macao, such as the Pharmaceutical Supervision Bureau, Health Bureau, Civil Aviation Bureau, Customs, and airlines, highly value the implementation of the CAR-T project at Kiang Wu Hospital. They are accelerating administrative approval processes and making every effort to resolve difficulties and bottlenecks in each aspect of two-way logistics.Approved Yikaida in September 2023^®As the first cell therapy drug approved in Macao, China, helping patients in the Macao region access globally leading CAR-T treatment drugs more quickly and promptly.